Medulloblastoma is a rare tumor in adults and the use of adjuvant chemotherapy in average risk patients is debated.
Methods:
Patients included in our study were ⩾16 years of age, had histologically confirmed medulloblastoma, and underwent adjuvant radiotherapy with or without chemotherapy. Average risk was defined according to the Chang classification.
Results:
We included 48 average-risk patients. Median follow-up was 151.5 months (95% confidence interval, 124.5–178.5). Both progression-free survival (PFS) and overall survival (OS) were significantly influenced by adjuvant chemotherapy (PFS: hazard ratio [HR], 0.334, p = 0.05; OS: HR, 0.187, p = 0.017) and by receiving the treatment in a referral center (PFS: HR, 0.250, p = 0.008; OS: HR, 0.295, p = 0.038).
Conclusions:
Treating patients with average-risk medulloblastoma in a referral center improves both PFS and OS, does adding adjuvant chemotherapy.
Peris-BonetRMartínez-GarcíaCLacourB, et al. Childhood central nervous system tumours: incidence and survival in Europe (1978-1997): report from Automated Childhood Cancer Information System project. Eur J Cancer2006; 42: 2064–2080.
2.
SmollNRDrummondKJ.The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci2012; 19: 1541–1544.
3.
BrandesAAFranceschiETosoniA, et al. Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer2007; 110: 2035–2041.
4.
FranceschiEHoferSBrandesAA, et al. EANO-EURACAN Clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncol2019; 20: e715–e728.
5.
BrandesAAErmaniMAmistaP, et al. The treatment of adults with medulloblastoma: a prospective study. Int J Radiat Oncol Biol Phys2003; 57: 755–761.
6.
QianLZhenguoDYuzeC, et al. Comparing children and adults with medulloblastoma: a SEER based analysis. Oncotarget2018; 9: 30189–30198.
7.
ZhangNOuyangTHuicongK, et al. Adult medulloblastoma: clinical characters, prognostic factors, outcomes and patterns of relapse. J Neuro-Oncol2015; 124: 255–264.
8.
AtalarBOzsahinMCallJ, et al. Treatment outcome and prognostic factors for adult patients with medulloblastoma: the Rare Cancer Network (RCN) experience. Radiother Oncol2018; 127: 96–102.
9.
AbaciogluUUzelOSengozM, et al. Medulloblastoma in adults: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys2002; 54: 855–860.
10.
AngCHauerstockDGuiotMC, et al. Characteristics and outcomes of medulloblastoma in adults. Pediatr Blood Cancer2008; 51:603–607.
11.
KunschnerLJKutteschJHessK, et al. Survival and recurrence factors in adult medulloblastoma: the MD Anderson Cancer Center experience from 1978 to 1998. Neuro-Oncol2001; 3: 167–173.
12.
RiffaudLSaikaliSLerayE, et al. Survival and prognostic factors in a series of adults with medulloblastomas. J Neurosurg2009; 111: 478–487.
13.
PackerRJGoldweinJNicholsonHS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol1999; 17: 2127–2136.
14.
PackerRJGajjarAVezinaG, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol2006; 24: 4202–4208.
15.
PadovaniLSunyachMPPerolD, et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys2007; 68: 433–440.
16.
KannBHLester-CollNHParkHS, et al. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncol2017; 19: 259–269.
17.
AtalarBOzsahinMCallJ, et al. Treatment outcome and prognostic factors for adult patients with medulloblastoma: the Rare Cancer Network (RCN) experience. Radiother Oncol2018; 127: 96–102.
18.
LambertiGFranceschiETosoniA, et al. Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: long-term results. J Clin Oncol2019; 37 (suppl): abstract 2037.
19.
BrandesAAFranceschiEErmaniM, et al. Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: results from a prospective population-based registry. Could survival differ in a high-volume center?Neurooncol Pract2014; 1: 166–171.
20.
MurrayMJBartelsUNishikawaR, et al. Consensus on the management of intracranial germ-cell tumours. Lancet Oncol2015; 16: e470–e477.
21.
GronchiAStraussDCMiceliR, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the Multi-institutional Collaborative RPS Working Group. Ann Surg2016; 263: 1002–1009.
